Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children

Next Previous
X
Search
Trial Profile

A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium thiosulfate (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Sponsors Fennec Pharmaceuticals

    • Most Recent Events

    • 06 Jun 2023 According to a Fennec Pharmaceuticals media release, the company received marketing authorization by the European Commission for Pedmarqsi (sodium thiosulfate) in pediatric patients with localized, non-metastatic solid tumors, based on SIOPEL 6 and Clinical Oncology Group [COG] Protocol ACCL0431). The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
    • 31 Mar 2023 According to a Fennec Pharmaceuticals media release, ratification of the CHMP recommendation is expected by early June 2023.
    • 31 Mar 2023 According to a Fennec Pharmaceuticals media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion and recommended granting a Marketing Authorization for Pedmarqsi for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localized, non-metastatic, solid tumors, based on SIOPEL 6 and Clinical Oncology Group [COG] Protocol ACCL0431.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top